CURRICULUM VITAE

Dr. Evangelos Kolettas, B.Sc.(HONS)(LON), Ph.D.(LON)

PERSONAL DETAILS

Name: **Evangelos Kolettas, B.Sc.**(Hons)(LON), **Ph.D.**(LON)

Positions:
- ***Professor of Molecular Cell Biology***, Laboratory of Biology, School of Medicine, Faculty of Health Sciences, University of Ioannina (UoI), Greece
- ***Group Leader/PI***, *Molecular Cancer Biology and Senescence* (*MCBS*) Group Biomedical Research Institute (BRI), Foundation for Research & Technology (FORTH), Ioannina, Greece

Place of Birth: Greece **Nationality:** Greek **Sex:** Male

Work address: Laboratory of Biology, School of Medicine, Faculty of Health Sciences
University of Ioannina, University Campus, 45110 Ioannina, Greece

Work Tel.: 0030-26510-07578 (office); 0030-26510-07758 (lab) **Fax:** 0030-26510-07863
E-mail Work: ekoletas@uoi.gr; evangelos_kolettas@bri.forth.gr; **Personal:** ekoletas@gmail.com
Skype: evangelos.kolettas
Websites: https://www.bri.forth.gr/en/research-en/item/5510-evangelos-kolettas
https://urci.unit.uoi.gr/ibs/en/index.html

Networks/Databases

Linkedin:	https://www.linkedin.com/in/kolettas/
Google scholar:	https://scholar.google.com/citations?user=3hbUwhIAAAAJ&hl=en
ResearchGate:	https://www.researchgate.net/profile/Evangelos_Kolettas
Scopus Author ID:	6602856311
ORCID ID:	https://orcid.org/0000-0002-5820-487X
SciProfile:	https://sciprofiles.com/user/publications/400313

EDUCATION:

1. Apolytirion (Graduation Certificate), 2nd Boys Lyceum, Ioannina, Greece

2. South East London Technical College (SELTEC), Lewisham, SE4 1UT, London, UK.
- G.C.E. 'A' Levels:
  - Pure Mathematics (632), Grade 'B' (Associated examining Board/AEB – part of AQA), 1979
  - Modern Greek (715), Grade 'E' (University of London examining Board), 1980
- Certificate in English for foreign students, Grade '3' (Pass)(Joint Matriculation Board/JMB), 1981

3. *Higher Diploma* (HD/HND) *in Applied Biology*, Biology Depertment, Sunderland Polytechnic, 1983
Diploma Projects (1982 - 1983):
(a) Investigation of the ascorbic acid oxidase activity in different plant tissues (*Biochemistry*)
(b) Isolation of soil actinomycetes and investigation of antibiotic production using different substrates and microorganisms such as *E. coli*, *S. aureus, P. fluorescens* and *B. subtilis* as bacterial markers for antibiotic production by the isolated soil actinomycetes. (*Microbiology*)

4. *BSc* (*Hons*) *in Biochemistry* (2.1), Department of Biochemistry, King's College, University of London, 1986
BSc Project: *The effects of various fatty acids upon the rate of elastolysis of bovine ligamentum nuchae elastin by porcine pancreatic elastase*
Supervisor: Prof. Harold Baum, PhD, FRSC, FIBiol, Head of Biochemistry Dept., KCL

5. *Ph.D. in Biochemistry* (*Genetics*), Department of Biochemistry, King's College, University of London and Genetics Division, MRC National Institute for Medical Research, London, 1990
PhD Thesis: '*Factors involved in the immortalisation and neoplastic transformation of rodent and human embryonic fibroblasts*', University of London
Supervisors: Drs Robin Holliday, FRS and Robert F. Rosenberger Genetics Division, MRC NIMR; Dr. Alan Hipkiss, Department of Biochemistry, KCL

Continuing Education: 6-12 week short online courses leading to *Statement of Accomplishment* in:

1. *Experimental Genome Science*, University of Pennsylvania, USA; 03/02/2013
2. *Introduction to Genetics and Evolution*, Duke University, USA; 09/04/2013
3. *Epigenetic Control of Gene Expression*, University of Melbourne, Australia; 05/09/2013
4. *Introductory Human Physiology*, Duke University, USA; 14/11/2013
5. *Genes and Human Condition*: *From Behaviour to Biotechnology*, Maryland University; 7/1/2014

EXPERIENCE:

- Teaching: *Molecular Cell Biology*, *Genetics/Molecular Genetics, Biochemistry*, *Cell Signalling*, C*ancer & Stem Cell Biology*, *Molecular Medicine* (*human disease*), *Human Physiology*
- Research: *Molecular Cancer Biology & Senescence*: Cell signalling & regulatory networks in DNA damage & inflammation impacting on senescence & cancer using *in vitro* & *in vivo* novel cell & bitransgenic mouse models; bioimaging, Retro/lentivectors, CRISPR/Cas9 & -omics technologies
- Achievements & Publications related to expertise on *Senescence, DNA damage & Cancer*:
  1. *Chondrocyte senescence and differentiation* [Kolettas *et al* (1995) Expression of cartilage-specific molecules remains unaffected by long-term culture of human articular chondrocytes. *J. Cell Sci*]
  2. *Cytokine regulation of chondrocyte differentiation and survival* [Kolettas *et al* (2001). Chondrocyte phenotype and cell survival are regulated by culture conditions and by specific cytokines through the expression of *Sox9* transcription factor. *Rheumatology*]
  3. *RIS1, a Ras-induced senescence marker & tumour-suppressor* [Barradas *et al* (2002) Identification of a candidate tumour suppressor gene specifically activated during *ras*-induced senescence. *Exp Cell Res*]
  4. *DNA damage responses in OIS act as a tumour barrier* [Bartkova *et al* (2006) Oncogene-induced senescence is part of the tumourigenesis barrier imposed by DNA damage checkpoints. *Nature*]
  5. *NFκB delays OIS* [Batsi *et al* (2009) Chronic NFκB activation delays *Ras*-induced premature senescence of human fibroblasts by suppressing the DNA damage checkpoint response. *Mech Ageing Dev*]
  6. *Bcl2-NFκB axis controls cancer cell apoptosis* [Batsi *et al* (2009) Bcl-2 blocks 2-methoxyestradiol induced leukaemia cell apoptosis by a $p27^{Kip1}$ dependent G_1/S cell cycle arrest in conjunction with NF-κB activation. *Biochem Pharmacol*]
  7. *Cdc6 licenses tumour growth and EMT* [Sideridou *et al* (2011) Cdc6 represses E-cadherin transcription and activates adjacent replication origins. *J Cell Biol*]
  8. *Canonical IKKβ/NF-κB pathway protects normal and tumour human cells from H_2O_2-induced DDR-dependent senescence and apoptosis, respectively* [Sfikas *et al* (2012) The canonical NF-κB pathway differentially protects normal and human tumour cells from ROS-induced DNA damage. *Cell Signal*]
  9. *Comprehensive review on miRNAs in cancer* [Markopoulos *et al* (2017) A step-by-step miRNA guide to cancer development and metastasis. *Cell Oncol*]
  10. *Identification of senescence-associated miRNAs targeting cell cycle genes during replicative senescence* (*e.g., miR-221/222*) [Markopoulos *et al* (2017) Senescence-associated microRNAs target cell cycle regulation genes in human lung fibroblasts. *Exp Gerontol*]
  11. *NF-κB - miRNA network in inflammation and cancer* [Markopoulos *et al* (2018) Roles of NF-κB signalling in the regulation of miRNAs impacting on inflammation in cancer. *Biomedicines*]
  12. *IKKα functions as lung tumour suppressor in mice and humans* [Chavdoula *et al* (2019) CHUK/IKKα loss in lung epithelial cells enhances NSCLC growth associated with HIF upregulation. *Life Sci Alliance*]
  13. *IKKβ and p65 act as lung tumour promoters* [Roupakia *et al* (2021) Canonical NFκB promotes lung cell tumour growth by downregulating the metastasis suppressor CD82 and enhancing EMT. *Cancers*]
  14. *RelA/p65 and E2F1 cistromes have limited overlap and bind active chromatin even prior to immunogenic stimulation* [Foutadakis *et al* (2022) An expanded interplay network between NF-κB p65 (RelA) and E2F1 transcription factors: Roles in cell physiology and pathology. *Cancers*]

POSITIONS:

01/2023 - *Professor of Molecular Cell Biology*, Laboratory of Biology, School of Medicine, University of Ioannina (UoI), Greece, and

2007 - Present: *Group Leader*, Biomedical Research Institute (BRI), Foundation for Research & Technology (FORTH), Ioannina; https://www.bri.forth.gr/en/research-en/item/5510-evangelos-kolettas

Undergraduate Teaching (MBBS & MSci in Applied Biology & Biotechnology, MSci ABB):

- *Core Biology I & II*: Cell and Molecular Biology lectures (MBBS Core Biology I module co-lead)
- *Pathological Oncology* (optional course module): Molecular Basis of Cancer (MBBS)
- *Cell Signalling* (option): NF-κB signalling in DNA damage, inflammation and cancer (MSci ABB)
- *Biology of stem cells & applications in medicine* (module lead): Cell cycle of SCs; iPSCs; CSCs

Postgraduate Teaching:

1. MSc in Molecular Cell Biology and Biotechnology
- *Molecular Cell Biology*: Cell cycle regulation
- *Molecular Oncology* (module lead/co-lead): Principles of Carcinogenesis; Hallmarks of cancer

2. MSc in Basic Biomedical Sciences (until 2020)
- *Biology & Biochemistry*: RNA synthesis & control of gene expression; Protein synthesis
- *Genetic Engineering & Gene Therapy* (module lead): Recombinant DNA technology

Molecular Cancer Biology & Senescence Research Group

I. *Cell signalling and regulatory networks in DNA damage and inflammation impacting on ageing/senescence and cancer*:

1. *Functional roles and mechanisms of action of IKKα- and IKKβ-mediated NFκB-dependent or independent signalling, and IKK/NFκB-miRNA regulatory network in DNA damage & inflammation involved in ageing/senescence & cancer,* using novel *in vitro* cell culture systems generated by inducible retro/lentivectors and CRISPR/Cas9 technology, and *in vivo* novel mouse lung cancer models, and by employing biochemical & molecular cell biology techniques, bio-imaging and high-throughput molecular analysis (RNA-seq, nanostring miRNA technology & Proteomics) in conjunction with bioinformatics. Projects include:

(a) *Impact of IKKα and IKKβ signalling on K-Ras-mediated senescence of human fibroblasts*

(b) *Cellular and metabolic reprogramming in NSCLC bearing oncogenic K-Ras* or *EGFR mutations under normoxia and hypoxia, to identify novel NF-κB-regulated biomarkers and potential therapy targets*

(c) *IKK/NF-κB signaling in inflammation- and ROS-induced toxic effects and DNA damage leading to metabolic reprogramming and chromatin remodeling in health and disease* (e.g., *cancer*) *to identify biomarkers and potential therapy targets*

(d) *Impact of IKK/NF-κB signalling pathways on the crosstalk between drug-induced DNA damage responses* (*DDR*) *and the mitotic spindle assembly checkpoint (SAC)*, including oxidative stress & chemotherapeutics, using reporters, high-content bio-imaging and -omics.

2. *TP53 tumour suppressor pathway in DNA damage, senescence and cancer*, by employing human telomerised lung fibroblasts expressing different mutant p53 genes, and lung epithelial cancer cells with a different p53 status.

II. Functional domain-specific such as functional kinase- (or phosphatase) or transcription factor (TF)-specific CRISPR/Cas9 screens to identify novel regulators of cell growth and behaviour.

1. *CRISPR/Cas9-mediated functional kinase-specific screen to identify novel regulators of cell signalling involved in cancer cell growth and chemoresistance* (Funded).

2. *kinase or TF-specific CRISPR/Cas9 screens to identify novel regulators involved in* **(a)** *senescence bypass, and* **(b)** *the crosstalk between DDR & SAC using reporter cells expressing Tubulin-EGFP and NUMA-Cherry*, *bioimaging and -omics*

3. *Domain-specific CRISPR/Cas9 screen to identify epigenetic regulators of MSC senescence bypass*

6/2015 – 01/2023: ***Associate Professor of Molecular Cell Biology***, Laboratory of Biology, School of Medicine, UoI, Greece

Undergraduate and Postgraduate teaching, and Research: As above

2014 - 6/2015: ***Associate Professor of Physiology with emphasis in Molecular Physiology***, Laboratory of Biology, School of Medicine, FHS, UoI, Greece

Undergraduate and Postgraduate teaching, and Research: As above

2002 - 2014: ***Assistant Professor of Physiology with emphasis in Molecular Physiology***, Laboratory of Physiology, School of Medicine, UoI, Greece

Undergraduate Teaching in *Human Physiology*, MBBS (2003-2014):

- *Cell Physiology*, including *Biological Membrane Structure-Function and Transport*
- *Physiology of the Digestive System*

Postgraduate Teaching:

1. MSc in Agricultural Product Assurance & Quality (2003-2008): (a) *Genetically-modified organisms*, and (b) *Environmental pollution & mutagenesis*
2. MSc in Pain Control: *Physiology of the Digestive system* (2004-2013)
3. MSc in Agro-chemistry and Biological Products (2004-13): *Animal Biotechnology* (module lead)
4. MSc in Biotechnology (2008-2014)
   - *Molecular Biology of the Gene*: *Cell cycle regulation and Cancer*

Cancer Biology & Senescence Research Group:
Role of IKK-mediated NF-κB-dependent or -independent signalling in senescence and cancer

1998 - 2002: ***Professor TEI of Chemistry and Biochemistry***
Department of Aquaculture & Fisheries, Technological Education Institute (TEI) of Epirus, Greece

Undergraduate Teaching (Course modules lead):

- *Organic Chemistry*, *Fish Biochemistry*, *Fish Nutrition*, *Biotechnology of aquatic organisms*, to Diploma in Aquaculture and Fisheries, TEI of Epirus
- *Genetics*, Degree in Agro-ecology, UoI/TEI of Epirus, Ioannina

Research: *Fish Genetics*

1995 - 1998: ***Lecturer in Biochemistry*** (Fixed-term)
Laboratory of Biochemistry, School of Medicine, University of Thessaly, Larisa, Greece

Undergraduate Teaching:

- *Organic Chemistry*: Aldehydes and Ketones; Carboxylic acids
- *Biochemistry I*: Topics in general and metabolic biochemistry
- *Biochemistry II*: Biochemistry of connective tissues and extracellular matrix

Research: *Heat shock proteins in lymphocytes*

1997 - 1998: ***Lecturer in Genetics*** (Fixed-term), Laboratory of Genetics
Department of Agricultural Biotechnology, Agricultural University of Athens, Greece

Undergraduate Teaching: *Animal Biotechnology*

6/2 - 26/2/97: ***Visiting Research Scientist*** (Travel grant), Wellcome Trust Centre for Cell-Matrix Research, Biochemistry Division, School of Biological Sciences, University of Manchester

Research: *Modulation of chondrocyte differentiation by cytokines*

1996 - 1997: ***Lecturer in Biochemistry*** (Fixed-term), Department of Nursing
School of Health & Welfare Professions, TEI of Thessaly, Greece

Undergraduate Teaching*: Biochemistry* - general & metabolic biochemistry (course module lead)

1990 - 1994: *Postdoctoral Fellow*, *Arthritis and Rheumatism Research Council UK*,
Biochemistry Dept., Charing Cross and Westminster Medical School, London, UK

Research*: Chondrocyte growth, immortalisation and differentiation*

Undergraduate Teaching: *Biochemistry of Cancer* to MBBS and BSc Biochemistry students

1988 - 1990: *Experimental Demonstrator*, Department of Biochemistry, King's College London
Undergraduate Practical classes to MBBS, BDS and BSc Biochemistry students

ADMINISTRATIVE DUTIES: Member of the assembly of the Basic Medical Sciences Division, UoI; Member of the Scientific Council of BRI-FORTH; Internal & external assessor for academic staff selection/promotion committees in Greece & UK; MSc committee member; Course module development & lead; Research group leader, managing teams, consortia & budgets; Project/Thesis supervision & examination committees; MoUs between UoI, Cyprus & Brunel Universities and student electives; Editorial work; Journal & Grant reviewer in Greece, UK & international funders; Organisation of seminars, national & international conferences.

PROJECT / THESIS SUPERVISION

- Higher Diploma Projects: 4
- BSc Projects: 6 • MSci Projects: 2
- MSc theses: 9 (2 as co-supervisor) • MSc theses examination committees: 9
- PhD theses, as: (a) *Main supervisor*: 8 (7 completed) (b) *Co-supervisor*: 12 (9 completed)
  (c) PhD theses examination committees: 28 (1 at Nottingham Trent U & 1 at Brunel U)
- I act as an internal and external undergraduate and postgraduate project/theses examiner
- Postdoctoral Supervision: 4
- Mentoring early career researchers (Postdocs and lecturers): 13

PUBLICATIONS

- *Methods book series*: Two chapters in '*Cell and Tissue Culture*: *Laboratory Procedures*' (Wiley & Sons, Publ.), on gene transfer methods of oncogenes in mammalian cells (1994)
- *Book chapters in Greek*: Three chapters for a textbook '*Elements in Cell Biology*' (1997)
- *Books* / *Chapters*: Scientific co-editing / translation in Greek of Textbooks and/or Chapters (Ch):
  - '*Human Physiology*: *From Cells to Systems*', by L. Sherwood (2012) 8th edn, Cengage, Co-editor and translation/editing of Chapter 16: Digestive System (Academic Press, Greece, 2014)
  - '*Molecular Cell Biology*' by Lodish *et al* (2016), 8th edn, Freeman & Co; Co-editor and translation of Chapter 5: Fundamental Molecular Genetic Mechanisms (Utopia, Greece, May 2020)
  - '*Principles of Development*' by Wolpert *et al* (2019), 6th e, OUP, Ch1: *History & Basic Concepts*
- **54** abstracts/posters to national, British, European and international conferences/workshops.
- **51** publications in peer-reviewed journals (*Nature, J Cell Biol, Cell Res, J Cell Sci, Rheumatol, Life Sci Alliance, Cancers, Free Rad Biol Med, Biochem Pharmacol, J Cell Mol Med, Cell Signal, J Exp Clin Cancer Res, Biomedicines, Cells, Eur J Biochem, FEBS J, FEBS Lett, Exp Cell Res, Cell Oncol, Exp Gerontol, Mech Ageing Dev, J Cell Biochem, J Mol Biol, Mobile DNA, J Theor Biol, Arch Biochem Biophys, Mol Cell Biochem, Histol Histopathol, Biosci Rep, Int J Oncol, ACS Chem Biol, Sensors & Actuators: B. Chem, etc*).

EDITORIAL WORK

- Editorial board member of *BIOMEDICINES* (Section: '*Cancer Biology & Therapeutics*' (2022-24)(IF: 4.7) (https://www.mdpi.com/journal/biomedicines/sectioneditors/cancer)
- Editorial board member of *CANCERS* (Section: *Molecular Cancer Biology*) (2023-25)(IF:5.2) (Invited and Accepted)

- Guest co-editor for a special issue of the journal *CELLS* (2021-22) (IF: 6.0), on: '*The DNA Damage Response in Cell Physiology and Disease*' (https://www.mdpi.com/journal/cells/special_issues/Damage_Response)
- Guest co-editor for a joint special issue of the journal *CANCERS* (2021-22) (IF: 5.20), on: '*NF-κB signalling in cellular responses to threats, cancer development and therapy*' (https://www.mdpi.com/journal/cancers/special_issues/nuclear_factor_kappaB)
- Guest co-editor for a special issue of the journal *BIOMEDICINES* (2022-23) (IF: 4.70), on: '*Cellular and metabolic reprogramming in cancer*' (https://www.mdpi.com/journal/biomedicines/special_issues/1WIK3O97NC)

RESEARCH GRANTS (25 competitive grants as PI, co-PI, Consortium Coordinator or Member)

- 1997 - 2004: 8 grants (6 as PI), 51,000 €
- 2004 - 2009: 6 grants (4 as PI & 2 as co-PI), 340.500 €
- 2012 - 2016: 5 grants (1 as Coordinator, 3 as PI & 1 as Member), 1.865,000 €
- 2017 - 2019: 3 grants (2 as PI, 1 as member, 620,000 €

Current funding:

- 2022 - 2023: 1 BRI-FORTH Research Institute internal bridging grant, 10,000 €
- 2021 - 2023: 1 BIOMED-20 grant, 3 m €; (Coordinator: S. Georgatos; Member: E. Kolettas)

GRANT / JOURNAL REVIEWER

- 35 grant proposals submitted to national, European & International funding bodies, UKRI-BBSRC (1 Strategic longer & larger programme grant: Frontier Biosci 2020/21, 2 m£), Leverhulme Trust, WCR/AICR, Academy of Medical Sciences-UK, MRC South Africa, Czech Science Foundation.
- 77 papers (*Biochem J, Biochem Pharmacol, Biol Cell, Biomedicines, BMC Cancer, Cancers, JECCR, Cell Cycle, Cells, Cell Death Dis, Commun Biol, Exp Gerontol, FEBS J, J Cell Mol Med, J Cell Physiol, J Clin Invest, J Hepatol, Mech Ageing Dev, Oncogene, Open Biol, PLoS One, Stem Cells Transl Med*).
- Reviewed the outline of the book on '*MicroRNA in human malignancies*', by M. Negrini, G. A. Calin, C. M. Croce; 1st edition, Elsevier / Academic Press, 2022.

SCIENTIFIC COLLABORATORS

1. *National*: University of Ioannina, BRI-FORTH, University of Athens, Biomedical Research Foundation Academy of Athens (BRFAA), Democritus University of Thrace.
2. *European*: Brunel, Nottingham Trent, Sussex & Essex Universities, University Hospital of Heidelberg, Free U of Brussels, CRBM-Montpellier-France, Danish Cancer Institute
3. *International*: Stony Brook University NY, UPenn, New Mexico University, Iowa State University.

HONOURS and AWARDS (1985 - 2004): 7

SOCIETY MEMBERSHIP: Hellenic Society of Biochemistry and Molecular Biology, Hellenic Society of Biological Sciences, Hellenic Association for Molecular Cancer Research, International Cell Senescence Association, Cancer Epigenetics Society.

CONFERENCE/WORKSHOP ORGANISATION (Member of the organising/scientific committee)

- 3rd European NF-κB subunit workshop, Corfu, Greece (10/2016).
- 67th Hellenic Society of Biochem & Molecular Biology conference, Ioannina, Greece (11/2016)
- I am known to European, UK and US researchers in the field of NF-κB in health and disease

CONFERENCES (National, British, European and International Conferences attended): **43**

SCIENTIFIC LECTURES (Invited; National, Cyprus, UK including Essex, Sussex & Brunel U): **35**

PUBLICATIONS

I. *Textbooks and Textbook Chapters*

1. ***Elements of Cell Biology* (2007)** (Editors: Griva E, Salamoura A & Tzima E), EFYRA Publishing Co. (in Greek).
   - *Cell Cycle* (Chapter 13, pp 283-287)
   - *Multicellular organisms and tissues* (Chapter 15, pp 315-321), and
   - *Extracellular Matrix of Connective Tissue* (Chapter 16, pp323-355).

2. ***Human Physiology*: *From Cells to Systems*** by **Lauralee Sherwood, 8th International edition 2012, Brooks/Cole Cengage Learning**; Chapters 20, pp928.
   Scientific Co-editing of the translation in Greek of the textbook; *Co-editors*: **E. Kolettas**, Laboratory of Biology, School of Medicine, and A. Psarropoulou, Department of Applied Biology & Biotechnology, University of Ioannina; and
   Scientific editing/translation of Ch16: The Digestive System.
   Publishers: Academic Press, Greece (2014).

3. ***Molecular Cell Biology***, by **Lodish H, Berk A, Kaiser CA, Krieger M, Bretscher A, Ploegh H, Amon A and Martin KC, 2016, 8th edition, WH Freeman & Co**, 24 Chapters, pp1166.
   Scientific Co-editing of the translation in Greek of the textbook (Eds: **Kolettas E**, Marangos P & Georgatos SD), and Translation/editing of Chapter 5: *Fundamental Molecular Genetic Mechanisms* (Part II: Biomembranes, Genes & Gene Regulation), 2020; *Publishers*: Utopia Publishing Co., Greece (April 2020).

4. ***Principles of Development***, by **Wolpert L, Tickle C & Arias AM**, **2019, 6th e; Oxford University Press**.
   Scientific translation in Greek of the textbook Chapter 1: *History and Basic Concepts of Development*. *Publishers*: Broken Hill Publ. Ltd, Cyprus (May 2020), (P. Marangos, editor).

II. *Chapters in Book Series* (2)

1. **Kolettas E**, Gonos ES and Spandidos DA. (1994)**.** Retroviral genes - *Myc*. Chapter 26: Immortalisation Methods, Units 26.7.1, Part 26H, Module 26H:1. In ***Cell and Tissue Culture*: *Laboratory Procedures*** (Griffiths JB, Doyle A & Newell DG, Eds), John Wiley & Sons, Ltd.

2. Gonos ES. **Kolettas E** and Spandidos DA. (1994). Retroviral genes - *Ras*. Chapter 26: Immortalisation Methods, Units 26.7.2, Part 26H, Module 26H:2. In ***Cell and Tissue Culture*: *Laboratory Procedures*** (Griffiths JB, Doyle A & Newell DG, Eds), John Wiley & Sons, Ltd.

III. *Conferences Oral Presentations & Posters*: 41 at National, British & International conferences

1. **Kolettas E**. (1988). Isolation and characterisation of genes which can suppress permanent cell growth and neoplastic transformation in mammalian cells. *Poster* 23, EMBO/CRC/NIEHS (EMBO/Cancer Research Campaign/National Institute of Environmental Health Sciences) Workshop on '*Tumour Suppressor genes and Negative growth regulation'*, Nethybridge, Scotland, 17-21 April 1988.
2. **Kolettas E**, Mason RMM and Muir HI. (1993). Differential responses of growth factor- and oncogene-expressing human keratinocytes to transforming growth factor (TGF)β1. *Poster* 72*,* CRC/Beatson Institute International Cancer Conference on '*The cellular, molecular and clinical aspects of squamous cell carcinomas*', Glasgow, Scotland, July 1993.
3. **Kolettas E**, Yu RCH, Harper K, Mason RMM and Muir HI. (1993). Heparin inhibits the growth of human keratinocytes: The effects of oncogenes encoding protein tyrosine kinases (PTKs). *Oral Presentation* 13*,* Annual Meeting of the British Society for Investigative Dermatology, Nottingham, UK, 20-21 September 1993*.*
4. **Kolettas E** and Muir HI. (1993). Human articular chondrocyte expression of type II collagen is retained on long-term culture and is unaffected by SV40 large-T antigen expression. *Poster* 19*,*

British Connective Tissue Society Workshop on '*Cartilage structure and Osteoarthritis*', Lilly Research Centre, Earl Wood, Windlesham, Surrey, UK, 21 May 1993.

5. **Kolettas E** and Muir HI. (1993). Changes in extracellular matrix gene expression by SV40 transformation in human fibroblasts. *Oral Presentation*, West London Matrix Biology Group meeting on '*The Molecular basis of extracellular matrix in health & disease*', Imperial College, London, 23 November 1993.
6. **Kolettas E**, Owen RD, Barrett JC and Muir HI. (1996). Regulation of phenotypic expression and cell survival by cytokines and cultured conditions in mammalian chondrocytes. *Hellenic Biochemical Society (HBS) Newsletter* 41:57-58.
7. **Kolettas E**, Santra M, Iozzo RV and Muir HI. (1996). Regulation of decorin gene expression by cytoplasmic oncogenes in human cells. *HBS Newsletter* 41:45-46.
8. **Kolettas E**, Kovatcev D and Bonanou-Tzedaki S. (1997). Expression of hsp70 in thalassaemic mononuclear cells. *Poster* 9, Molecular & Cellular Pharmacology group meeting of the Biochemical Society on '*Cellular responses to stress*', Dundee University, UK, 29-31/7/1997
9. **Kolettas E**, Hardingham TE, Muir HI and Barrett JC. (2000). Inhibition of the chondrocyte phenotype and cell survival by IL-1 is mediated by the master chondrocyte-regulatory *Sox9* gene and is relieved by IGF-1. *Poster* E35, XVIIth FECTS meeting, University of Patras, Greece, 1-5 July 2000.
10. **Kolettas E**, Barrett JC and Muir HI. (2000). Neither SV40 large-T antigen expression nor immortalisation by itself abrogates chondrocyte-specific gene expression. *Poster* E36, XVIIth FECTS Meeting, University of Patras, Greece, 1-5 July 2000.
11. **Kolettas E**, Evangelou A, Bonanou-Tzedaki S and Gonos ES. (2000). Thermal responses and cell survival of a spontaneously immortalised human keratinocyte cell line and oncogene-expressing lines derived from it: Role of heat shock proteins and clusterin/apoJ. *Poster* 1423, 18th International Congress of Biochemistry and Molecular Biology on '*Beyond the Genome: Understanding and exploiting molecules and cells in the 3rd millennium*', International Convention Centre, Birmingham, England, 26-20 July 2000.
12. **Kolettas E**, Tenopoulou M, Galaris D, Gonos ES and Evangelou A (2000). Vanadium inhibits HaCaT cell proliferation but it does not induce apoptosis. *Poster*, FESTEM Meeting, Venice, Italy, 16-21 May 2000.
13. Kontargiris E, **Kolettas E**, Vadalouca A, Koutsoukou V, Evangelou A and Kalfakakou V. (2002). Zn-Endopeptidase (NEP) related to ropivacaine effects on HaCaT cells. *Abstract* OP41, pp 112; 'ALGOS 2002', World Institute of Pain Int. Symposium, Santorini, Greece, 21-24/09/2002
14. Kontargiris E, Kalfakakou V, Vadalouca A, Evangelou A, Gonos ES and **Kolettas E**. (2002). Ropivacaine-induced apoptosis of HaCaT cells is blocked by ectopic expression of clusterin/apolipoprotein J. *HSBMB Newsletter* 49:149-153 [Proceedings of the 54th Conference of the Hellenic Society of Biochemistry and Molecular Biology (HSBMB), Greece].
15. Tenopoulou M, **Kolettas E**, Frillingos S, Gonos ES and Galaris D. (2002). The role of clusterin (ApoJ) and Bcl-2 in DNA damage and apoptosis in cells exposed to H_2O_2. *HSBMB Newsletter* 49:341-345 (Proceedings of the 54th Conference of HSBMB, Greece).
16. Markopoulou S and **Kolettas E**. (2006). p53^{143ala} sensitised human diploid fibroblasts to C_2-ceramide-induced apoptosis: Role of Bcl-2. *Poster*, Hellenic Society of Biosciences, Athens, Greece, April 2006.
17. Markopoulou S, Batsi C, Thomas C, Kontargiris E. Evangelou A, Kanavaros P and **Kolettas E**. (2006). Overexpression of Bcl-2 protected Jurkat cells from 2-methoxyestradiol-induced apoptosis. *Poster*, 2nd InterCongress of Eur Soc of Pathology, Ioannina, Greece, 24-27/5/2006
18. Batsi C, Kanavaros P, Marcu KB and **Kolettas E**. (2006). Suppression of NF-κB activation pathway provokes premature senescence of human diploid fibroblasts. *HSBMB Newsletter* 53:37. (Proceedings of 58th HSBMB Conference), University of Patras, Greece, 9-11/11/2006.
19. Batsi C, Marcu KB and **Kolettas E**. (2007). The role of NF-κB in cellular senescence. *Poster*, 12th Congress of the International Association of Biomedical Gerontology on the '*Molecular Mechanisms and Models of Ageing*', Spetses Island, 20-24 May 2007.
20. **Kolettas E**. (2007). 2-methoxyestradiol, a promising anti-tumour agent: From basic research to the clinic. *Oral Presentation*, International Conference on '*Molecular Targets for Cancer Prevention, Diagnosis and Treatment*', University of Cyprus, Lemesos, Cyprus, 7-10/10/2007.

21. Kontargiris E, **Kolettas E**, Vadalouca A and Kalfakakou V. (2007). Role of Zn in ropivacaine and neutral endopeptidase: Toxic effects of human keratinocyte cells. *Poster*, *Cell Biology and Toxicology*, Abstract 8; P03:58. [Joint Conference on: '*Trace elements in diet, nutrition, and health: essentiality & toxicity*'], Creta Maris Conference Center, Hersonissos, Crete, 21-26/10/2007.
22. Batsi Ch, Kontargiris E, Markopoulou S, Trougakos IP, Gonos ES and **Kolettas E**. (2008). Vanadium-induced apoptosis of HaCaT cells is mediated by *c-fos* and involves up-regulation of nuclear clusterin/apolipoprotein J. *Oral Presentation*, 5th Clusterin/Apolipoprotein J (CLU) Workshop, Spetses island, 2-5 June 2008.
23. Tselikou E, Sfikas A, Batsi C, Vartholomatos G, Galaris D, Kanavaros E and **Kolettas E**. (2008). Pim-2, a serine/threonine protein kinase, protects human fibroblasts from H_2O_2-induced apoptosis. *Poster*, 6th Conference of the Hellenic Society of Free Radicals and Oxidative Stress, Ioannina, Greece, 18-21/9/2008.
24. Kontargiris E, Vadalouca A, **Kolettas E** and Kalfakakou V. (2009). Ropivacaine downregulates neutral endopeptidase and induces zinc-inhibited apoptosis on HaCaT cells. *Poster* 13, Int. Symposium of the Worldwide Institute of Pain 'ALGOS 2009', Mykonos, Greece, 18-21/6/2009
25. Primikyri A, Karali E, Chi S-W, **Kolettas E**, Briasoulis E, Fotsis T, Tzakos A and Gerothanassis I. (2012). Charting polyphenol-Bcl-2 and Bcl-X_L interactions by the use of NMR, calorimetry, docking calculations and *in vitro* studies. *Poster*, 15th Hellenic Symposium of Medicinal Chemistry, Athens, Greece, 25-27 May 2012.
26. Roupakia E, Markopoulos G, Kakaniaris N, Marcu KB and **Kolettas E**. (2014). Regulation of Cdc6 expression by NF-κB in response to DNA damage. *Poster* P146 (Regulation of Gene Expression), Proceedings, 65th Conference of Hellenic Society of Biochemistry & Molecular Biology (HSBMB), Thessaloniki, Greece, 28-30 November 2014.
27. Maltabe V, Bakavou E, Markopoulos G, Roupakia E, Marcu KB, **Kolettas E** and Kouklis P. (2014). IKKα promotes stem cell differentiation to endothelial cells. *Poster* P58 (Stem Cells & Tissue Regeneration), 65th HSBMB Conference, Thessaloniki, Greece, 28-30 November 2014.
28. Roupakia E, Markopoulos G, Polytarchou C, Hatziapostolou M and **Kolettas E**. (2015). Replicative or oncogene-induced senescence leads to differential miRNA expression in human diploid fibroblasts. *Poster* P015, 66th HSBMB Conference, Athens, Greece,11-13/12/2015
29. Chavdoula E, Stathopoulos GT, Marcu KB, Klinakis A and **Kolettas E**. (2015). Deletion of IKKβ reduces urethane-induced lung cancer development in mice. *Poster* P138, 66th HSBMB Conference, Athens, Greece, 11-13 December 2015.
30. Markopoulos G, Roupakia E, Eckerich C, Vartholomatos G, Fackelmayer FO, Marcu KB and **Kolettas E**. (2015). Uncovering an ATM - NF-κB positive feedback loop involved in DNA damage responses. *Poster* P163, 66th HSBMB Conference, Athens, Greece, 11-13/12/2015.
31. Gkartziou F, Noutsopoulos F, Vartholomatos G, Thrasyvoulou S, Mantziou S, **Kolettas E**, Markoula M, Georgiou I, Kyritsis A and Tzavaras T. (2015). Valproic acid induces HERV-K10 retrotransposition correlated with neural differentiation and growth arrest of human glioblastoma cells. *Poster* P160, 66th HSBMB Conference, Athens, Greece, 11-13 December 2015.
32. Mantziou S, Markopoulos G, Vartholomatos G, Gkartziou F, **Kolettas E** and Tzavaras T. (2015). Retrotransposition of a recombinant SVA retrotransposon is correlated with phenotypic changes at A549 cells. *Poster* P169, 66th HSBMB Conference, Athens, Greece, 11-13/12/2015.
33. Thrasyvoulou S, Vartholomatos G, Markopoulos G, Gkartziou F, Noutsopoulos D, Charchanti, A, **Kolettas E**, Constantinou AI and Tzavaras T. (2015). VL30 retrotransposition correlates with epithelial-mesenchymal transition and cancer stem cell generation in progenitor mouse epithelial breast cells. *Poster* P202, 66th HSBMB Conference, Athens, Greece, 11-13/12/2015.
34. Markopoulos G, Roupakia E, Tokamani M, Vartholomatos G, Hatziapostolou M, Sandaltzopoulos R, Polytarchou C, and **Kolettas E**. (2016). Deciphering the roles of microRNAs in the senescence response of human fibroblasts. *Poster* (*Ageing*), 67th HSBMB Conference, Ioannina, Greece, 24-27 November 2016.
35. Chavdoula E, Roupakia E, Markopoulos G, Kokkalis A, Polyzos A, Fackelmayer FO, Thanos D, Klinakis A, Marcu KB and **Kolettas E**. (2016). Functional role of IKKα in non-small cell lung carcinogenesis. *Poster* (*Molecular and Cellular Basis of Human Disease*), 67th HSBMB Conference, Ioannina, Greece, 24-27 November 2016.
36. Roupakia E, Chavdoula E, Markopoulos G, Fackelmayer FO, Klinakis A, Marcu KB and **Kolettas E**. (2016). Loss of IKKβ reduces cell proliferation and impairs lung cancer development. *Poster*

(*Molecular and Cellular Basis of Human Disease*), 67th HSBMB Conference, Ioannina, Greece, 24-27 November 2016.

37. Tokamani M, Miaoulis L, Karapetsas A, Polytarchou C, **Kolettas E** and Sandaltzopoulos R. (2016). MiRNAs linking the NF-κB signalling pathway with the RB/E2F regulatory circuitry. *Poster* (*Epigenetics and Regulation of Gene Expression*), 67th HSBMB Conference, Ioannina, Greece, 24-27 November 2016.
38. Kafetzopoulou K, Miaoulis E, Tokamani M, Markopoulos G, Roupakia E, **Kolettas E** and Sandaltzopoulos R. (2017). The gene expression regulators TFG, NFYB and DNM3 are targeted by miR-221/222. *Poster*, 68th HSBMB Conference, Athens, Greece, 10-12/11/2017.
39. Tokamani M, Korpidou M, Mourati S, Niavi C, Petkou K, Ziridou E, Sandaltzopoulou E, Ampartzidis I, Markopoulos G, Roupakia E, **Kolettas E** and Sandaltzopoulos R. (2017). MiR-342-3p targets *fosB* and *maf* in lung cancer linking canonical NF-κB activity to the regulation of cell proliferation. *Poster*, 68th HSBMB Conference, Athens, Greece, 10-12 November 2017.
40. Niavi C, Tokamani M, Mourati S, Korpidou M, Ziridou E, Sandaltzopoulou E, Markopoulos G, Roupakia E, **Kolettas E**, Sandaltzopoulos R. (2018). Deciphering an IKK/NF-κB-miRNA transcriptional regulatory network in NSCLC cell proliferation: Interaction between miR-342-3p and FOSB, MAF. *Poster* (*Biochemical & Molecular Biology*), 21st Annual Undergraduate Research Symposium in Chemical & Biological Sciences, UMBC, Baltimore, USA, 20/10/2018.
41. Roupakia E, Karpathiou G, Batistatou A, Goussia A and **Kolettas E**. (2021). Mechanisms of action of canonical NF-κB signalling pathway in lung carcinogenesis. 17th Annual Conference of the Panhellenic Society of Pathology, 23-26 June 2021 (online).

IV. ***Abstracts Published in Journals*** (**13**)

1. Yu RCH, Buluwela L, **Kolettas E**, Alaibac M and Chu AC. (1993). Comparison between the Cytomegalovirus early and Moloney murine leukaemia virus LTR promoters in their ability to produce transiently and stably transfected CD1a-expressing HeLa cells. ***J. Invest. Dermatol***. 100(4) (P40):436.
2. Yu RCH, **Kolettas E**, Buluwela L, Kamalati T, Alaibac M and Chu AC. (1993). Increased CD1a expression at lower temperatures by stably transfected Hela cells. ***J. Invest. Dermatol***. 100(4):443.
3. **Kolettas E** and Muir HI. (1994). Retroviral-mediated gene transfer into articular chondrocytes: a potential for gene therapy. (*Oral presentation* III-45, Session IIIB '*Potentials for Gene Therapy*', 5th International Conference on '*The Molecular Biology and Pathology of Matrix*', 19-12/06/1994, Medical College, Thomas Jefferson University, PA, USA). ***Matrix Biology*** 14:406.
4. **Kolettas E** and Muir HI. (1994). Isolation and characterisation of conditionally immortalised articular chondrocyte cell lines from adult homozygous *H-2K^b tsA58* transgenic mice. (*Abstract/Oral Presentation* IV-10, Session IV '*Expression of Normal and Mutated Genes in Cells and Men*', 5th International Conference on '*The Molecular Biology & Pathology of Matrix*', 19-12/06/1994, Jefferson Medical College, Thomas Jefferson University). ***Matrix Biology*** 14:410.
5. **Kolettas E**, Evangelou A, Bonanou-Tzedaki S and Gonos ES. (2000). Thermal responses and cell survival of a spontaneously immortalised human keratinocyte cell line and oncogene-expressing cell lines derived from it: role of heat shock proteins and clusterin/apoJ. ***Biochem. Soc. Trans***. 28(5):A373-A373.
6. Evangelou A, **Kolettas E**, Tenopoulou M, Galaris D, Gonos E and Manos G. (2002). Vanadium inhibits HaCaT cell proliferation but it does not induce apoptosis. ***Metal Ions Biol Med*** 7:154-8.
7. Charalambous Ch, Batsi Ch, **Kolettas E** and Constantinou AI. (2007). Induction of apoptosis by 2-methoxyestradiol in Jurkat cells is associated with topoisomerase II activation (*Abstract*/*Poster*, '*Cellular responses to anticancer Drugs*', Conference of the American Association of Cancer Research (AACR), Los Angeles, CA, USA, 2007). ***Cancer Res*** 67 (Suppl 9):3234.
8. Kontargiris E, **Kolettas E**, Vadalouca A and Kalfakakou V (2008) Role of Zn in ropivacaine and neutral endopeptidase: toxic effects on human keratinocyte cells. ***Cell Biol Toxicol***. 8.P03:58.
9. Batsi Ch, Kanavaros P, Marcu KB and **Kolettas E**. (2008). *Ras^{V12}*-induced premature senescence of human fibroblasts is rescued by constitutively activated *IKKβ* (*Abstract/Poster* 33rd FEBS Congress/11th IUBMB, Athens, 28/6-3/7, 2008). ***FEBS J***. 275(1):149.

10. Sfikas A, Galani V, Chondrogiannis G, Kastamoulas M, Vartholomatos G, Bai M, Markopoulou T, **Kolettas E** and Kanavaros P. (2008). TNFα effect on the cell death of the A549 lung carcinoma cells (*Abstract* 696, Eur Soc of Pathology, London, 10/2008). ***Histopathol***. (S1) 53:303.
11. Galani V, Chondrogiannis G, Kastamoulas M, Sfikas A, Vartholomatos G, Markopoulou T, Arvanitis D, **Kolettas E** and Kanavaros P. (2009). TNFα, IL1β, IL13 and IFNγ effects on the cell death of the A549 lung carcinoma cells (*Abstract/Poster P8-45,* 34th FEBS Congress, Prague, Czech Republic, 4-9/7/2009). ***FEBS J***. 276:310.
12. Galani V, Kastamoulas M, Chondrogiannis G, Vartholomatos G, Vlachopoulou E, Arvanitis, D, Liloglou, T, **Kolettas E**, Baltogiannis D, Sofikitis N and Kanavaros P. (2010). Cytokine effects on the cell cycle and death of lung and prostate carcinoma cells (*Abstract/Poster*, European Respiratory Society Annual Congress). ***Virchows Archives*** 457(2):231-232.
13. Primikyri A, Hatzimichael E, Karali E, Kostaras E, Manztaris M, Shin J-S, Chi S-W, **Kolettas E**, Gerothanassis I, Briasoulis E and Tzakos A (2013) Decoding the BH3-mimetic pro-apoptotic activity of quercetin in Jurkat cells (*Poster* 1672, 5th American Soc of Hematology annual meeting, Session-*Chemical Biol & Exp Therapeutics*, 7-10/12/2013, New Orleans, US). ***Blood*** 122(21):1672.

V. *Full Publications in Greek Periodicals* (**1**)

Kolettas E. (2005). 2-methoxyestradiol, a promising anti-tumour agent: From basic research to the clinic. ***Forum in Clinical Oncology*** 4(2-3):172-179.

VI. *Journal Publications* (**51**) (IF, Impact Factor)

1. Rosenberger RF, Gounaris EG and **Kolettas E**. (1991). Mechanisms responsible for the limited and immortal phenotype in cultured mammalian cells. ***J Theor Biol*** 148:383-392 (IF:2.0)
2. **Kolettas E***, Gonos ES and Spandidos DA. (1994). Overexpression of *Ha-Ras* oncogene transforms rodent fibroblasts with low frequency but not human diploid fibroblasts. ***Int. J. Oncol***. 4:43-47. (IF: 5.2)
3. **Kolettas E**, Buluwela L, Bayliss MT and Muir HI. (1995). Expression of cartilage-specific molecules remains unaffected by long-term culture of human articular chondrocytes. ***J. Cell Sci***. 108:1991-1999. (IF: 4.0)
4. **Kolettas E***, Spandidos DA and Rosenberger RF. (1997). SV40 transformation of embryonic human diploid fibroblasts results in multiple changes in gene expression. ***Int. J. Oncol***. 11(4):717-725. (IF: 5.2)
5. **Kolettas E***, Khazaie K and Rosenberger RF. (1997). Overexpression of the human *c-erbB* (*EGF Receptor*) proto-oncogene fails to alter the lifespan or promote tumourigenic growth of normal and SV40-transformed human fibroblasts. ***Int. J. Oncol***. 11(5):1071-1080. (IF: 5.2)
6. Yu RCH, **Kolettas E**, Kamalati T, Chu AC and Buluwela L. (1997). Stable expression of CD1a molecule in human epithelial cell lines shows temperature-dependent expression and affects cell morphology and growth. ***Arch. Dermatol. Res***. 289(6):352-359. (IF: 3.0)
7. **Kolettas E***, Lymboura M, Khazaie K and Luqmani YA. (1998). Modulation of human elongation factor 1-delta gene expression by oncogenes in human epithelial cells. ***Anticancer Res***. 18:385-92 (IF: 2.0)
8. **Kolettas E** and Rosenberger RF. (1998). Suppression of decorin gene expression and induction of anchorage-independent growth by overexpression of *v-src* oncogene in human fibroblasts. ***Eur. J. Biochem***. (***FEBS J***) 254(2):266-274. (IF: 5.4)
9. Assimakopoulos DA, **Kolettas E**, Zagorianakou N, Evangelou A, Skevas A and Agnantis N. (2000). Prognostic significance of p53 in the cancer of the larynx. ***Anticancer Res***. 20(5):3555-3564 (Invited Review). (IF: 2.0)
10. Paschos I, Natsis L, Nathanailidis C, Kagalou I and **Kolettas E**. (2001). Induction of androgenesis and gynogenesis in the goldfish *Carassius auratus* oranda. ***Reproduction in Domestic Animals*** 36(3-4):195-198. (IF: 1.70)
11. **Kolettas E***, Muir HI, Barrett JC and Hardingham TE. (2001). Chondrocyte phenotype and cell survival are regulated by culture conditions and by specific cytokines through the expression of *Sox9* transcription factor. ***Rheumatology*** 40(10):1146-1156. (IF: 5.5)

12. **Kolettas E***, Evangelou E and Gonos ES. (2001). *v-FBR-fos* oncogene fails to rescue mammalian cells from growth arrest but affects the responses of human fibroblasts to heparin. ***Anticancer Res***. 21(1A):435-444. (IF: 2.0)
13. Petropoulou C, Trougakos I, **Kolettas E**, Toussaint O and Gonos ES. (2001). Clusterin / Apolipoprotein J is a novel biomarker of cellular senescence that does not affect the proliferative capacity of human diploid fibroblasts. ***FEBS Lett***. 509:287-297. (IF: 3.5)
14. Barradas M, Gonos ES, Zebedee Z, **Kolettas E**, Petropoulou C, Delgado MD, Leon J, Hara E and Serrano M. (2002). Identification of a candidate tumour suppressor gene specifically activated during *ras*-induced senescence. ***Exp. Cell Res***. 173(2):127-137. (IF: 3.70)
15. Gonos ES, Agrafiotis D, Dontas AS, Efthimiopoulos S, Galaris D, Karamanos NK, Kletsas D, **Kolettas E**, Panagyotou G, Sekeri-Pataryas KE, Simoes D, Sourlingas TG, Stathakos D, Stratigos AJ, Tavernarakis N, Trougakos IP, Tsiganos CP and Vinyos DH. (2002). Ageing Research in Greece. ***Exp. Gerontol***. 37(6):735-747. (IF: 3.90)
16. Assimakopoulos DA, **Kolettas E**, Evangelou A and Patrikakos G. (2002). The role of CD44 in the development and prognosis of squamous cell carcinoma of head and neck. ***Histol. Histopathol***. 17(4):1269-1281. (Invited Review). (IF: 2.0)
17. Charalabopoulos K, Papalimneou V, Evangelou A, Kalfakakou V, Kiortsis D, **Kolettas E**, Alamanos J, Charalabopoulos A and Agnantis NJ. (2003). Is the E-cadherin downregulation observed in Helicobacter pylori infection associated with gastric cancer development? An additional element in the disease jigsaw. ***Exp. Oncol***. 25(4):270-273. (IF: -)
18. Kontargiris E, **Kolettas E**, Vadalouca A, Trougakos IP, Gonos ES and Kalfakakou V. (2004). Ectopic expression of clusterin/apolipoprotein J or Bcl-2 decreases the sensitivity of HaCaT cells to toxic effects of ropivacaine. ***Cell Res***. 14(5):415-422. (IF: 44.10) (*NPG Journals*)
19. Bartkova J, Rezai N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, **Kolettas E**, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Ørntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J and Gorgoulis VG. (2006). Oncogene-induced senescence is part of the tumourigenesis barrier imposed by DNA damage checkpoints. ***Nature*** 444 (7119):633-637. (IF: 64.80) (Suppl:www.nature.com/nature/journal/v444/n7119/suppinfo/nature05268.html); *A seminal paper*
20. **Kolettas E***, Skoufos I, Kontargiris E, Markopoulou S, Tzavaras T and Gonos ES. (2006). Bcl-2 but not clusterin/apolipoprotein J protected human diploid fibroblasts and immortalised keratinocytes from ceramide-induced apoptosis: Role of p53 in the ceramide response. ***Arch. Biochem. Biophys***. 445:184-195. (IF: 3.90)
21. **Kolettas E***, Thomas C, Leneti E, Skoufos I, Mbatsi C, Sisoula C, Manos M and Evangelou A. (2006). Rosmarinic acid failed to suppress hydrogen peroxide-mediated apoptosis but induced apoptosis of Jurkat cells which was suppressed by Bcl2. ***Mol Cell Biochem*** 285:111-20(IF:4.3)
22. Barbouti AK, Amorgianiotis CG, **Kolettas EM**, Kanavaros PE and Galaris DA. (2007). Hydrogen peroxide inhibits caspase-dependent apoptosis by inactivating procaspase-9 in an iron-dependent manner. ***Free Rad. Biol. Med***. 43:1377-1387. (IF: 7.40) (see commentary: https://www.sciencedirect.com/science/article/pii/S0891584907005552).
23. Noutsopoulos D, Markopoulos G, Koliou M, Dova L, Vartholomatos G, **Kolettas E** and Tzavaras T. (2007). Vanadium induces VL30 retrotransposition at an unusually high level: a possible carcinogenesis mechanism. ***J. Mol. Biol***. 374:80-90. (IF: 5.60)
24. Markopoulou S, Kontargiris E, Batsi C, Tzavaras T, Trougakos IP, Boothman DA, Gonos ES and **Kolettas E*.** (2009). Vanadium-induced apoptosis of HaCaT cells is mediated by *c-fos* and involves nuclear accumulation of clusterin. ***FEBS J***. 276:4208-4223. (IF: 5.40)
25. Batsi C, Markopoulou S, Vartholomatos G, Georgiou I, Kanavaros P, Gorgoulis VG, Marcu KB and **Kolettas E***. (2009). Chronic NF-κB activation delays Ras^{V12}-induced premature senescence of human fibroblasts by suppressing the DNA damage checkpoint response. ***Mech. Ageing Dev***. 13:409-419. (IF: 5.30)
26. Batsi C, Markopoulou S, Kontargiris E, Charalambous Ch, Thomas Ch, Christoforidis S, Kanavaros P, Constantinou AI, Marcu KB and **Kolettas E***. (2009). Bcl-2 blocks 2-methoxyestradiol induced leukaemia cell apoptosis by a $p27^{Kip1}$ dependent G_1/S cell cycle arrest in conjunction with NF-κB activation. ***Biochem. Pharmacol***. 78:33-44. (IF: 5.80)
27. Noutsopoulos D, Markopoulos G, Vartholomatos G, **Kolettas E**, Kolaitis N and Tzavaras T. (2010). VL30 retrotransposition signals activation of the mitochondrial death pathway in a

caspase-independent and p53- and lysosomal damage-dependent manner. ***Cell Res***. 20:553-562. (IF: 44.10) (*NPG Journals*)

28. Sigala F, Savvari P, Liontos M, Sigalas P, Pateras IS, Papalampros A, Basdra E, **Kolettas E**, Kotsinas A, Papavassiliou AG and Gorgoulis VG. (2010). Increased expression of bFGF is associated with carotid atheromatic plaques instability engaging the NF-κB pathway. ***J. Cell. Mol. Med***. 14:2273-2280. (IF: 5.30)

29. Sideridou M, Zakopoulou R, Evangelou K, Liontos M, Kotsinas A, Rampakakis E, Gagos S, Kahata K, Grabusic K, Gkouskou K, Trougakos IP, **Kolettas E**, Georgakilas G, Volarevic S, Eliopoulos AG, Zannis-Hadjopoulos M, Moustakas A and Gorgoulis VG. (2011). Cdc6 expression represses E-cadherin transcription and activates adjacent replication origins. ***J. Cell Biol***. 195:1123-1140 [*In Focus*: Leslie M (2011) Cdc6 licenses tumour growth.*JCB* 195:106] (IF: 7.80)

30. Konisti S, Mantziou S, Markopoulos G, Thrasyvoulou S, Vartholomatos G, Sainis I, **Kolettas E**, Noutsopoulos D and Tzavaras T. (2012). H_2O_2 signals via iron induction of VL30 retrotransposition correlated with cytotoxicity. ***Free Rad. Biol. Med***. 52:2072-81 (IF: 7.40)

31. Sfikas A, Batsi C, Tselikou E, Monokrousos N, Pappas P, Vartholomatos G, Christoforidis C, Tzavaras T, Kanavaros P, Gorgoulis VG, Marcu KB and **Kolettas E***. (2012). The canonical NF-κB pathway differentially protects normal and human tumour cells from ROS-induced DNA damage. ***Cellular Signalling*** 24:2007-2023. (IF: 4.80)

32. Primikyri A, Chatziathanasiadou M, Karali E, Kostaras E, Mantzaris M, Hatzimichael E, Shin J-S, Chi S-W, Briasoulis E, **Kolettas E**, Gerothanassis IP and Tzakos AG. (2014). Direct binding of Bcl-2 family proteins by quercetin triggers its pro-apoptotic activity. ***ACS Chem. Biol***. 9:2737-2741. (IF: 4.0)

33. Karapetsas A, Tokamani M, **Kolettas E** and Sandaltzopoulos R. (2015). Novel microRNAs as putative therapeutic targets in cardiovascular diseases. ***Curr. Vascular Pharmacol***. 13(5):564-565. (*Editorial*) (IF: 4.50)

34. Markopoulos G, Noutsopoulos D, Mantziou S, Gerogiannis D, Thrasyvoulou S, Vartholomatos G, **Kolettas E** and Tzavaras T. (2016). Genomic analysis of mouse VL30 retrotransposons. ***Mobile DNA*** 7:10, May 6 (10.1186/s13100-016-0066-8) (IF: 4.90)

35. Markopoulos G, Roupakia E, Tokamani M, Chavdoula E, Hatziapostolou M, Polytarchou C Marcu KB, Papavassiliou AG, Sandaltzopoulos R and **Kolettas E***. (2017). A step-by-step microRNA guide to cancer development and metastasis. ***Cell Oncol***. 40(4):303-339. (IF: 6.60)

36. Markopoulos G, Roupakia E, Tokamani M, Vartholomatos G, Tzavaras T, Hatziapostolou M, Fackelmayer FO, Sandaltzopoulos R, Polytarchou C and **Kolettas E***. (2017). Senescence-associated microRNAs target cell cycle regulation genes in human lung fibroblasts. ***Exp. Gerontol***. 96:110-122. (IF: 3.90)

37. Ypsilantis K, Plakatouras JC, Manos MJ, Kourtellaris A, Markopoulos G, **Kolettas E** and Garoufis A. (2018). Stepwise synthesis, characterization, DNA binding properties and cytotoxicity of diruthenium oligopyridine compounds conjugated with peptides. ***Dalton Transactions*** 47(10):3549-3567. (IF: 4.0)

38. Patounas O, Papacharalampous I, Eckerich C, Markopoulos G, **Kolettas E** and Fackelmayer FO. (2018). A novel splicing isoform of Protein Arginine Methyltransferase 1 (PRMT1) that lacks the dimerization arm and correlates with cellular malignancy. ***J. Cell. Biochem***. 119(2):2110-2123. (IF: 4.0)

39. Markopoulos G, Roupakia E, Tokamani M, Alabasi G, Sandaltzopoulos R, Marcu KB and **Kolettas E***. (2018). Roles of NF-κB signalling in the regulation of miRNAs impacting on inflammation in cancer. ***Biomedicines*** 6(2):40,198-216 (10.3390/biomedicines6020040)(IF:4.7)

40. Roupakia E, Markopoulos G and **Kolettas E***. (2018). IL-12-mediated transcriptional regulation of matrix metalloproteinases. ***Bioscience Rep***. 38(3) BSR20171420 (*Commentary*) (IF: 4.0)

41. Sundar D, Yu Y, Katiyar SP, Putri J, Dhanjal JK, Wang J, Sari AN, **Kolettas E**, Kaul SC and Wadhwa R. (2019). Wild type p53 function in $p53^{Y220C}$ mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: Bioinformatics and experimental evidence. ***J. Exp. Clin. Cancer Res***. 38(1):103 (1-14) (IF: 11.30) (*BMC-Springer Nature*)

42. Markopoulos G, Roupakia E, Marcu KB and **Kolettas E***. (2019). Epigenetic regulation of inflammatory cytokine-induced epithelial-to-mesenchymal cell transition and in the generation of cancer stem cells. ***Cells*** 8(10), Sep 25, pii: E1143 (10.3390/cells8101143). (IF: 6.0)

43. Chavdoula E, Habiel DM, Roupakia E, Markopoulos GS, Vasilaki E, Kokkalis A, Polyzos A, Boleti H, Thanos D, Klinakis A, **Kolettas E*** and Marcu KB*. (2019). CHUK/IKKα loss in lung epithelial cells enhances non-small cell lung cancer (NSCLC) growth associated with HIF up-regulation. ***Life Science Alliance*** 2(6):e201900460 (10.26508/lsa.201900460). (IF: 5.781)
LSA is a journal of the EMBO Press, Rockefeller University Press & Cold Spring Harbor Lab Press.

44. Ntellas P, Mavroeidis L, Gkoura S, Gazouli I, Amylidou A-L, Papadaki A, Zarkavelis G, Mauri D, Karpathiou G, **Kolettas E**, Batistatou A and Pentheroudakis G. (2020). Old player-new tricks: Non angiogenic effects of the VEGF/VEGFR pathway in cancer. ***Cancers*** 12(11):E3145 (10.3390/cancers12113145) (IF: 5.2)

45. Tsiailanis A, Renziehausen A, Kiriakidi S, Vrettos EI, Markopoulos GS, Sayyad N, Hirmiz B, Aguilar M-I, Del Borgo MP, **Kolettas E**, Widdop RE, Mavromoustakos T, Crook T, Syed N and Tzakos AG. (2020). Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid. ***Free Rad. Biol. Med***. 160:391-402. (IF: 7.40)

46. Roupakia E, Markopoulos GS and **Kolettas E***. (2021). Genes and pathways involved in senescence bypass identified by functional genetic screens. ***Mech. Ageing Dev***. Jan 8; 194:111432 (10.1016/j.mad.2021.111432) (IF: 5.30)
For the special MAD issue on '*The bright and dark side of cellular senescence*' (Eds: V.G. Gorgoulis, University of Athens Medical School, Greece; R. DiMicco, Telethon Institute for Gene Therapy, Ospedale San Raffaele, Milan, Italy; M. Kovatcheva, Institute for Research in Biomedicine, Barcelona, Spain; https://www.sciencedirect.com/journal/mechanisms-of-ageing-and-development/special-issue/10S35Q64NBZ)

47. Basagiannis D, Zografou S, Goula E, Gkeka D, **Kolettas E** and Christoforidis S. (2021). Chemical inhibitors of dynamin exert differential effects in VEGF signalling. ***Cells*** 10(5):997; (10.3390/cells10050997) (IF: 6.0)

48. Diamantis DA, Agalou A, Chatziathanasiadou MV, Markopoulos GS, Bellou S, Kanaki Z, Crook T, Syed N, Rampias T, Klinakis A, **Kolettas E**, Beis D and Tzakos AG. (2021). Biotin-Yellow a biotin guided NIR turn-on fluorescent probe for cancer targeted diagnosis. ***Sensors and Actuators: B. Chemical*** 337:129807 (10.1016/j.snb.2021.129807). (IF: 8.40)

49. Roupakia E, Chavdoula E, Karpathiou G, Vatsellas G, Hatzopoulos D, Kriegsmann K, Kriegsmann M, Mela A, Gillette JM, Batistatou A, Goussia A, Marcu KB, Karteris E, Klinakis A and **Kolettas E***. (2021). Canonical NF-κB promotes lung epithelial cell tumour growth by downregulating the metastasis suppressor CD82 and enhancing epithelial-to-mesenchymal cell transition. ***Cancers*** 13(17):4302. doi:10.3390/cancers13174302 (IF: 5.20)

50. Foutadakis S, Roupakia E, Liakopoulos P, Kolovos P* and **Kolettas E***. (2022). An expanded interplay network between NF-κB p65 (RelA) and E2F1 transcription factors: Roles in cell physiology and pathology. ***Cancers*** 14:5047 (10.3390/cancers14205047) (IF: 5.20)

51. Ntinopoulou M, Cassimos D, Roupakia E, **Kolettas E**, Panopoulou M, Mantadakis E, Konstandinidis Th and Chrysanthopoulou A. (2023). IL-17A-enriched Neutrophil Extracellular Traps promote immunofibrotic aspects of childhood asthma lung attack. ***Biomedicines*** 11 (8):2104 (doi.org/10.3390/biomedicines11082104) (IF: 4.70)

(*correspondence)

METRICS

- **Total Journal Impact factor 2023:** 460
- **Citations**:

Google Scholar:	> 4030,	*h*25;	http://scholar.google.gr/citations?user=3hbUwhIAAAAJ&hl=el
Scopus:	> 2850,	*h*21;	https://www.scopus.com/authid/detail.uri?authorId=6602856311
ResearchGate:	> 3730,	*h*23;	https://www.researchgate.net/profile/Evangelos_Kolettas

CONFERENCES (**43** National, British, European and International Conferences attended)

1. EMBO/CRC/NIEHS Workshop on '*Tumour Suppressor Genes and Negative Growth Regulation*', Nethybridge, Scotland, UK, 17-21 April 1988.
2. Royal Society Workshop on '*DNA Methylation and Gene Expression*', London, UK, 03/1988.
3. MRC National Institute for Medical Research Scientific Conference on '*Developmental Biology*

and Cellular Processes', University of Warwick, Coventry, England, UK, 22-23/09/1988.

4. British Society for Cell Biology & British Connective Tissue International Society Meeting on '*Cell Biology of Cartilage & Bone*', Christ Church College, University of Oxford, 17-20/09/1990.
5. Inaugural Symposium of the CRC/Wellcome Trust Institute of Developmental Biology and Cancer, on '*Developmental Biology and Cancer*', University of Cambridge, UK, July 1991.
6. West London Cancer Research Group Meeting on '*Cellular, Molecular and Clinical aspects* of *Cancer', Charing Cross & Westminster Medical School, University of London, UK, 08/05/1992.
7. '*Wound Healing*' workshop, British Society for Research into Ageing, King's Fund Centre, London, UK, 15 February 1993.
8. British Connective Tissue Society workshop on '*Cartilage Structure and Osteoarthritis*', Lilly Research Centre, Earl Wood, Windlesham, Surrey, England, UK, 21 May 1993.
9. CRC/Beatson Institute International Cancer Conference on ''*The clinical, cellular and molecular aspects* of *squamous cell carcinomas*', Glasgow, Scotland, UK, 11-15 July 1993.
10. Annual Meeting of the British Society for Investigative Dermatology, on '*Cellular, molecular and clinical Dermatology*', University of Nottingham, England, 20-21 September 1993.
11. Meeting of the British Association for Cancer Research and the British Royal Society of Surgery, on '*Cellular, Molecular and Clinical Oncology*', London, England, UK, 19/11/1993.
12. Meeting of West London Matrix Biology Group on '*The molecular basis* of *extracellular matrix in health and disease*', Imperial College, University of London, UK, 23 November 1993.
13. The Royal Society, meeting on '*Death from inside out*: *The role* of *apoptosis in development, tissue homeostasis and malignancy*', London, England, UK, 23-24 February 1994.
14. Meeting of the West London Matrix Biology Group on '*Current research in matrix biology*', Imperial College, University of London, England, UK, 10 March 1994.
15. 5th International Conference on '*The molecular biology and pathology* of *matrix*', Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, USA, 19-22 June 1994.
16. 45th Conference of the Hellenic Society of Biochemistry & Biophysics, University of Patras, Greece, 10-11 May 1996.
17. 4th Conference, Hellenic Society of Connective Tissue Research, Athens, Greece, 13/05/2000.
18. XVIIth FECTS meeting, University of Patras, Patras, Greece, 1-5 July 2000.
19. 54th Conference of the Hellenic Society of Biochemistry & Molecular Biology (HSBMB), University of Ioannina, Greece, 10-12 October 2002.
20. 28th Conference of Hellenic Society of Biological Sciences, Ioannina, Greece, 18-20 May 2006.
21. 58th Conference of the HSBMB, University of Patras, Greece, 9-11 November 2006.
22. 12th Congress, Int. Association of Biomedical Gerontology, Spetses, Greece, 20-24/5/2007.
23. International Conference on '*Molecular targets for cancer prevention, diagnosis and treatment*', University of Cyprus, Lemesos, Cyprus, 7 -10 October 2008.
24. 59th Conference of the HSBMB, Athens, Greece, 7-9 December 2007.
25. 5th *Clusterin/Apolipoprotein J* (CLU) Workshop, Spetses Island, 2-5 June 2008.
26. 6th Conference, Society of Free Radicals & Oxidative Stress, Ioannina, Greece, 18-21/9/2008.
27. 1st International Molecular Cancer Research Conference, on '*Inflammation & Cancer*', '*Cancer signalling pathways & crosstalks*' and '*Targeted therapies in cancer*', Hellenic Association for Molecular Cancer Research, Royal Olympic Hotel, Athens, Greece, 27-29/11/2009
28. Workshop on '*Genomic determinants of inflammation*' organised by the EU FP7-funded research consortium '*Model-In'*, Hotel Amarilia, Vouliagmeni, Athens, Greece, 2-3 April 2012.
29. '*1st European NF-κB subunit workshop*' (organised by Prof N. Perkins, Newcastle University & Prof. L. Schmitz, Justus-Liebig University of Giessen), University of Giessen, Germany, 1-3/10/2012.
30. 1st World Hellenic Biomedical Association (WHBA) postgraduate symposium in '*Translational Medicine*' with the support of the University of Ioannina. Round Table with Prof. Harald zur Hausen (Nobel Laureate), Dr. K. Drosatos, WHBA President, Ioannina, Greece, 28/02/2012.
31. Scientific meeting of the Institute of Molecular Biology and Biotechnology (IMBB), Foundation of Research & Technology (FORTH), Herakleion, Crete, Greece, 27-28 April 2013.
32. INsPiRE international workshop on: '*Oncogenic pathways & antitumour responses*', Biomedical Research Foundation Academy of Athens (BRFAA), Greece, 23-25/04/2014.
33. '*2nd European NF-κB subunit workshop*' [organised by Drs S. Rocha (Dundee), N. Perkins, (Newcastle), R. Carmody (Glasgow) & L. Stark (Edinburgh), K. Campbell (Glasgow)], Atholl Palace Spa Hotel, Pitlochry, Scotland, UK, 6-8 October 2014.

34. 65th Conference of the HSBMB, Thessaloniki, Greece, 9-11 November 2014.
35. 1st International workshop on '*Reshaping drug discover*: *The intrinsically disordered proteome as drug target*' [*Organising Committee:* K. Dunker (USA), A. Tzakos (GR)], UoI, Greece, 19/06/2015.
36. 66th Conference of the HSBMB, Eugenides Foundation, Athens, Greece, 11-13/12/2015.
37. Scientific meeting of the Institute of Molecular Biology & Biotechnology (IMBB), Foundation of Research & Technology (FORTH), Herakleion, Crete, Greece, 20-22 May 2016.
38. '*3rd European NF-κB subunit workshop*', Corfu Chandris Hotel & Villas, Dassia, Corfu, Greece, 3-5 October 2016 (http://nf-kappab.eu/); [Member of the organising/scientific committee: D. Thanos (BRFAA), E. Kolettas (UoI), M. Angelopoulos (BRFAA), G. Mosialos (AUTH)]
39. 67th Conference of Hellenic Society of Biochemistry & Molecular Biology, Conference Center, UoI, Greece, 24-27 2016; Member of the organising/scientific committee (www.eebmb2016.gr)
40. 12th Molecular Oncology & Targeted Therapies Workshop, Round table Chair on '*Genomic atlases of solid tumours*', organised by the Department of Medical Oncology, University of Ioannina Medical School (UoIMS), the Oncology Clinic, UoI Hospital, and the Society for Tumour heterogeneity, Hotel Du Lac, Ioannina, Greece, 31/3-1/4, 2018.
41. '13rd Molecular oncology & targeted therapies' workshop, organised by the: Department of Medical Oncology, UoIMS & Oncology Clinic, UoI Hospital, and the Society for Tumour heterogeneity, Greece, 29-30 March 2019.
42. 17th Annual Congress of the Panhellenic Society of Pathology, 23-26 June 2021 (Virtual, online).
43. '14th Molecular oncology & targeted therapies' workshop. Session Chair 08/09/2023, organised by the: Department of Medical Oncology, UoIMS & Oncology Clinic, UoI Hospital, and the Society for Tumour heterogeneity, Greece, 07-09 September 2023.

SCIENTIFIC LECTURES (**35** as Invited speaker)

1. '*Cooperation* of *ras and myc oncogenes in rat and human embryonic fibroblasts*'. Biochemistry, Dept., Charing Cross & Westminster Medical School, London (Prof. Alan Malcolm), 18/01/1991
2. '*Role* of *cytoplasmic and nuclear oncogenes on rat and human embryonic fibroblasts*'. Anatomy Dept., University of Cardiff College of Medicine, Wales (Prof. Charles Archer), 8/12/1991.
3. '*Attempts to immortalise human articular chondrocytes using temperature-sensitive oncogenes delivered by retroviral-mediated gene transfer*'. Division of Biochemistry, Kennedy Institute of Rheumatology, Hammersmith, London, UK (Dr M. Bayliss & Prof Tim Hardingham), 12/03/1992
4. '*Comparison of the effects of the collaborating cytoplasmic and nuclear oncogenes on human and rat cells*'. Biology Lab, University of Ioannina Med Sch, Greece (Dr T. Tzavaras), 6/12/1993
5. '*Heparin inhibits the growth of human keratinocytes: The effects of oncogenes encoding protein tyrosine kinases* (PTKs)'. Annual Meeting of the British Society for Investigative Dermatology, Nottingham, UK, 20-21 September 1993.
6. '*The effects of a thermolabile SV40 large T-antigen on human chondrocytes*'. Biochemistry Lab, Chemistry Dept., University of Patras, Greece (Dr D. Vinyos & Prof. C. Tsiganos), 26/10/1993.
7. '*Isolation and characterisation* of *conditionally immortalised articular chondrocyte cell lines from adult homozygous H-2K^b tsA58 transgenic mice*'. West London Matrix Biology Group meeting, Imperial College, University of London, UK, 10 March 1994.
8. '*Use* of *conditionally immortalised articular chondrocyte cell lines isolated from adult homozygous H-2K^b tsA58 transgenic mice*'. 5th International Conference on '*The Molecular Biology and Pathology of Matrix*'. Thomas Jefferson University, PA, USA (Organisers: Prof. Darwin Prockop, Thomas Jefferson U & Prof. Bjorn R. Olsen, Harvard Medical School), 19-22/06/1994
9. '*Regulation of decorin gene expression by cytoplasmic oncogenes in a spontaneously-immortalised human keratinocyte line*'. Department of Medical Oncology, Charing Cross & Westminster Medical School, University of London (Prof. Charles Coombes), 9/9/1994.
10. '*Regulation of decorin gene expression by cytoplasmic oncogenes'*, 45th Conference of Hellenic Society of Biochemistry & Biophysics (HSBB), University of Patras, Greece, 10-11 May 1996.
11. '*Regulation of phenotypic expression and survival of mammalian chondrocytes by cytokines and culture conditions*', 45th Conference of HSBB, University of Patras, Greece, 10-11/05/1996
12. '*Factors regulating mammalian chondrocyte growth, differentiation and cell survival*'. Wellcome Trust Centre for Cell-Matrix Research/Biochemistry Division, University of Manchester, UK (Prof. Tim Hardingham), 24 February 1997.

13. '*Regulation of phenotypic expression and survival of mammalian chondrocytes by cytokines and culture conditions*', Laboratory of Molecular Oncology, Institute of Biology & Biotechnology, National Hellenic Research Foundation, (Dr. Efstathios S. Gonos), 18 April 1997.
14. '*Regulation of chondocyte survival*'. 4th Conference of the Hellenic Society of Connective Tissue Research, Hippokrateion Hospital, Athens, (Dr Aris Charonis), 13 May 2000.
15. '*Probing the mechanisms of action of collaborating viral ras and myc oncogenes in mammalian cells*'. Centro Unificato di Ricerca Biomedica Applicata (CURBA), University of Bologna, Italy, (Prof. P. Chieco and Ken B. Marcu, CURBA, University of Bologna, Italy), 16 October 2002.
16. '*The role of oncogenic stress on the homeostasis of human fibroblasts*', Dermatology Clinic, University Hospital Medical School, University of Ioannina (Prof. I. Hatzis), 11 February 2004.
17. '*Bcl-2-mediated apoptotic block is linked to cell cycle arrest*'. Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus, (Prof. A. I. Constantinou), 10 December 2004.
18. '*Bcl-2-mediated apoptotic block to 2-methoxyestradiol linked to G_1/S cell cycle arrest involves nuclear association of Bcl-2 and up-regulation of $p27^{Kip1}$*'. UoI Med School, Greece, 15/3/2006.
19. '*The role of Bcl-2 on 2-methoxyestradiol-induced apoptosis*'. Laboratory of Biological Chemistry, University of Ioannina Medical School, Greece, 29 April 2006.
20. '*Constitutively activated IKKβ rescues human diploid fibroblasts from RasV12-induced premature senescence*'. 58th HSBMB Conference, University of Patras, Greece, 9-11/11/2006.
21. '*2-methoxyestradiol: From basic science to clinical applications*'. Interdepartmental scientific lectures on Molecular Oncology, University of Ioannina, Greece, 01 May 2007.
22. '*2-methoxyestradiol, a promising antitumour agent: From basic research to the clinic*', *International Conference on 'Molecular targets for cancer prevention, diagnosis and treatment*', University of Cyprus, Lemesos, Cyprus, 7-10 October 2008.
23. '*Vanadium-induced apoptosis of HaCaT cells is mediated by c-fos and involves up-regulation of nuclear clusterin/apolipoprotein J*'. 5th Clu/Apo J workshop, Spetses, Greece, 2-5/06/2008
24. ''*The role of NF-κB on replicative and oxidative-stress-induced senescence*'. 6th Hellenic Conference of the Society of Free Radicals & Oxidative Stress, Ioannina, 18-21/09/2008.
25. '*The role of NF-κB on DNA damage responses*', Biology Lab, UoIMS, Greece, 5/6/2009
26. '*Functional roles and mechanisms of action of IKKα- and IKKβ-mediated NF-κB signalling during lung carcinogenesis*'', 1st World Hellenic Biomedical Association (WHBA) post-graduate symposium in *Translational Medicine*, University of Ioannina, 28 February 2012.
27. '*Function of NF-κB catalytic subunits in cell proliferation and lung cancer*', Scientific meeting of the Institute of Molecular Biology and Biotechnology (IMBB), Foundation for Research & Technology (FORTH), Herakleion, Crete, Greece, 27-28 April 2013.
28. '*Impact of IKKα on cell growth and urethane-induced lung tumourigenesis*', Scientific meeting of the IMBB-FORTH, Herakleion, Crete, Greece, 20-22 May 2016.
29. '*Different functional roles of IKKα and IKKβ in NSCLC development*''. '*3rd European NF-κB subunit workshop*', Chandris Hotel, Corfu, Greece, 3-5 October 2016 (http://nf-kappab.eu/).
30. '*An IKKβ-miRNA pathway involved in oncogene-initiated senescence*', Fondation Santé Fellows Symposium (organiser Prof. S. Artavanis-Tsakonas), Ionic Centre, Plaka, Athens, 06/10/2017
31. '*NF-κB - miRNA Regulatory Network in non-small cell lung cancer*'. Invited speaker, 12th Molecular Oncology & Targeted Therapies Workshop, organised by the: Society for Tumour heterogeneity, Department of Medical Oncology, University of Ioannina Medical School & Oncology Clinic University Hospital, Ioannina, Greece, 30-31/03/2018.
32. '*Role of tetraspanins in cell homeostasis and cancer*'. Invited speaker, 13rd Molecular Oncology & Targeted Therapies Workshop, organised by the: Society for Tumour heterogeneity, Medical Oncology Dept., UoI Medical School & University Hospital of Ioannina, 29-30/03/2019.
33. '*Impact of canonical versus noncanonical NF-κB signalling in lung carcinogenesis*', School of Life Sciences, University of Essex, Colchester, UK (Dr. Charalampos Rallis), 18/02/2021.
34. '*Canonical vs noncanonical NF-κB signalling in lung carcinogenesis*', Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, UK (Prof. Georgios Giamas, Head of the Department of Biochemistry & Biomedicine), 16/04/2021.
35. '*NF-κB signalling pathways in lung carcinogenesis*', Division of Biosciences, Department of Life Sciences, College of Health, Medicine & Life Sciences, Brunel University London, UK (Dr. Emmanouil Karteris, Reader in Biomedical Sciences), 16/03/2023 (live).